Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PAEDIATRIC RHEUMATOLOGY

2021 ACR guideline for JIA reflects changes in practice

Nature Reviews Rheumatology volume 18, pages 369–370 (2022)Cite this article

Subjects

The new ACR guideline for the treatment of juvenile idiopathic arthritis provides an update on several important topics, including management of oligoarthritis, temporomandibular joint arthritis and systemic-onset arthritis. Overall, the new guideline reflects changes in practice, but also highlights a concerning lack of high-quality evidence.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465–482 (2011).

    Article  Google Scholar 

  2. Ringold, S. et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 65, 2499–2512 (2013).

    Article  Google Scholar 

  3. Onel, K. B. et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 74, 553–569 (2022).

    Article  Google Scholar 

  4. Stoll, M. L. et al. Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in juvenile idiopathic arthritis. J. Rheumatol. 45, 1301–1307 (2018).

    Article  Google Scholar 

  5. Ter Haar, N. M. et al. Treatment to Target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 71, 1163–1173 (2019).

    Article  Google Scholar 

  6. Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396–2406 (2012).

    Article  CAS  Google Scholar 

  7. De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385–2395 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Mediche Traslazionali, Sezione di Pediatria, Università degli Studi di Napoli Federico II, Naples, Italy

    Roberta Naddei

  2. Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy

    Roberta Naddei

  3. Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy

    Angelo Ravelli

  4. Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), Università degli Studi di Genova, Genoa, Italy

    Angelo Ravelli

Authors
  1. Roberta Naddei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo Ravelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Ravelli.

Ethics declarations

Competing interests

A.R. declares that he received honoraria and research grants from Abbvie, Alexion, Angelini, BMS, Novartis, Pfizer, Reckitt-Benkiser, Roche and SOBI. R.N. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naddei, R., Ravelli, A. 2021 ACR guideline for JIA reflects changes in practice. Nat Rev Rheumatol 18, 369–370 (2022). https://doi.org/10.1038/s41584-022-00787-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-022-00787-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing